ライフサイエンスコーパス: lactamase

1 or a cryptic allosteric site in CTX-M-9 beta-lactamase.

2 ts of single amino acid InDels in TEM-1 beta-lactamase.

3 s only bactericidal after activation by beta-lactamase.

4 ity was not observed in strains without beta-lactamase.

5 affecting bacteria that do not produce beta-lactamase.

6 oint mutants of a single protein, TEM-1 beta-lactamase.

7 s between sequential mutations in TEM-1 beta-lactamase.

8 ng an AmpC and 11 coproducing a metallo-beta-lactamase.

9 for the beta-lactam resistance enzyme, beta-lactamase.

10 neumoniae carbapenemase (KPC-2) class A beta-lactamase.

11 isolates coproducing an AmpC or metallo-beta-lactamase.

12 ion rate compared with the common TEM-1 beta-lactamase.

13 m scaffold to avoid hydrolysis by KPC-2 beta-lactamase.

14 ith MDR P. aeruginosa that lack metallo-beta-lactamases.

15 the contexts of hydrolysis by different beta-lactamases.

16 ing proteins, or for the related serine beta-lactamases.

17 terial cell walls and can be cleaved by beta-lactamases.

18 and monobactams), by the production of beta-lactamases.

19 genes coding for extended-spectrum SHV beta-lactamases.

20 (ESBLs), AmpCs, K1, and broad-spectrum beta-lactamases.

21 sitive detection of clinically-relevant beta-lactamases.

22 tivity against class A, C, and D serine beta-lactamases.

23 pectrum beta-lactamases (ESBL) and AmpC beta-lactamases.

24 d inhibitors of serine and some metallo beta-lactamases.

25 ins or the structurally similar class D beta-lactamases.

26 ntibiotics, including extended-spectrum beta-lactamases.

27 nt to hydrolysis by all four classes of beta-lactamases.

28 istance genes, including those encoding beta-lactamases.

29 istance, specifically New Delhi metallo-beta-lactamase-1 (NDM-1).

30 e Carbapenemase-4 and New Delhi Metallo-beta-Lactamase-1 in the United States, recognition of the mol

31 eriaceae that produce extended-spectrum beta-lactamases (82.4% vs. 75.0%).

32 Two chromosomally encoded inducible beta-lactamases, a Pen-like class A and AmpC are produced in

33 beta-lactamase activity in humans has been neglected, even th

34 us studies have demonstrated that their beta-lactamase activity is comparable to those of well-known

35 f: mutations that increase the enzyme's beta-lactamase activity tend to increase also its susceptibil

36 of the other MBLAC2 role as a bona fide beta-lactamase allows for reassessment of beta-lactams and be

37 nd in the library, docking against AmpC beta-lactamase (AmpC) and the D(4) dopamine receptor were sim

38 asmic events that lead to expression of beta-lactamase, an antibiotic-resistance determinant.

39 ndonuclease CPSF-73, containing metallo-beta-lactamase and beta-CASP domains and a cluster of conserv

40 nterestingly, in addition to the metalo-beta-lactamase and beta-CASP domains, RNase J of plants conta

41 ies, and characterized the conjugative, beta-lactamase and cryptic plasmids.

42 re all ST106, and encoded for blaACT-15 beta-lactamase and fosfomycin resistance (fosA).

43 but also distinguishes between metallo-beta-lactamase and serine-carbapenemase production in P. aeru

44 ly couple to metalloproteins related to beta-lactamases and nitric oxide reductases.

45 it clinically relevant class A, C and D beta-lactamases and penicillin-binding proteins, resulting in

46 een the inhibition efficacy of purified beta-lactamases and the potentiation of beta-lactam antibacte

47 ant strains producing extended-spectrum beta-lactamases and/or carbapenemases.

48 minants of beta-lactam resistance (e.g. beta-lactamase) and redox potential in Mtb.

49 oli (ESBL) (producing extended spectrum beta-lactamases) and Morganella morganii.

50 mutations in the Escherichia coli TEM-1 beta-lactamase antibiotic resistance gene using growth compet

51 beta-Lactamases are a major threat to the clinical use of car

52 The hydrolytic enzymes called beta-lactamases are responsible for a large proportion of the

53 Finally, beta-lactamases are widely distributed, archaic, and have wid

54 CTX-M beta-lactamases are widespread in Gram-negative bacterial pat

55 g to AMR, including seven class A and C beta-lactamases as well as mutations in gyrA and parC recogni

56 spergillus niger, and the TEM-family of beta-lactamase associated with antibiotic resistance.

57 se enzymes, carbapenemases or ampC type beta-lactamases, at least one of which was detected in most,

58 ant E. coli isolates expressing diverse beta-lactamases; bactericidal activity was not observed in st

59 The beta-Lactamase (BL) enzyme family is an important class of en

60 ere based on the absence or presence of beta-lactamase (bla) NDM, VIM, IMP, KPC, and OXA carbapenemas

61 petitive inhibition of the M. abscessus beta-lactamase, Bla(Mab), using a novel assay, which is valid

62 ulosis (Mtb) expresses a broad-spectrum beta-lactamase (BlaC) that mediates resistance to one of the

63 arry the recently characterized metallo-beta-lactamase blaSPR-1 that, although not conferring high le

64 beta-Lactamases (BLs) able to hydrolyze beta-lactam antibioti

65 a-lactam antibiotic action by producing beta-lactamases (BLs), including carbapenemases, which are ab

66 a bicyclic boronate inhibit L2 (serine beta-lactamase) but not L1 (metallo beta-lactamase) from the

67 ows stability to most extended spectrum beta-lactamases, but is considered inactive against Pseudomon

68 lity to hydrolyze penicillins, emergent beta-lactamases can now confer resistance to other beta-lacta

69 entration, as shown by the treatment of beta-lactamase-carrying Escherichia coli with cefotaxime.

70 ravel the ambiguity surrounding class A beta-lactamase catalysis, we have used ultrahigh-resolution X

71 to beta-lactam antibiotics is via their beta-lactamase-catalyzed hydrolysis.

72 to four classes; the active-site serine beta-lactamases (classes A, C and D) and the zinc-dependent o

73 drug that combines ciprofloxacin with a beta-lactamase-cleavable motif.

74 itive and specific for the detection of beta-lactamase compared to the blaZ PCR results, whereas the

75 trap the acyl-enzyme complex of class A beta-lactamase CTX-M-14 at varying pHs.

76 globally distributed extended-spectrum beta-lactamase CTX-M-15, and find three non-synonymous mutati

77 action outcomes and mechanisms by which beta-lactamases degrade carbapenems are still not fully under

78 ly overlooked in the well-studied TEM-1 beta-lactamase demonstrates the utility of exposons.

79 beta-Lactamases divide into four classes; the active-site ser

80 roduct complexes for a wild-type serine beta-lactamase, elucidating the product release mechanism of

81 were KPC (K. pneumoniae carbapenemases) beta-lactamases encoded by blaKPC2, blaKPC3, and blaKPC4, whi

82 genome carrying only an f1 origin and a beta-lactamase-encoding (bla) antibiotic resistance gene, ena

83 s performed on all isolates to identify beta-lactamase-encoding genes.

84 genes (ARGs), including those encoding beta-lactamase enzymes (BLA), which degrade commonly prescrib

85 ism of action of the different types of beta-lactamase enzymes as a basis for inhibitor design and ta

86 yptic allosteric sites in two different beta-lactamase enzymes that are widespread sources of antibio

87 In Gram-negative bacteria, beta-lactamase enzymes that hydrolyze the amide bond of the f

88 uld be explained by inhibitor-resistant beta-lactamase enzymes, carbapenemases or ampC type beta-lact

89 DHA-1) and class A (TEM-1 and CTX-M-2) beta-lactamase enzymes, respectively.

90 -negative bacteria is the production of beta-lactamase enzymes.

91 inhibitors of both serine- and metallo-beta-lactamase enzymes.

92 eract antibiotic resistance mediated by beta-lactamase enzymes.

93 pid rise in the number and diversity of beta-lactamases, enzymes that inactivate beta-lactams, a clas

94 nt bacteria including extended-spectrum beta-lactamase (ESBL) and carbapenem-resistant Enterobacteria

95 plasmid bearing a single extended-spectrum B-lactamase (ESBL) gene (bla(CTX-M-14)).

96 g pressure has driven extended-spectrum beta-lactamase (ESBL) gene acquisition and evolution in patho

97 hylococcus aureus and extended-spectrum beta lactamase (ESBL) incidence were explained by background

98 terobacteriaceae with extended spectrum beta-lactamase (ESBL) or fluoroquinolone resistance rose sign

99 thin-host dynamics of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae.

100 an infection with an extended spectrum beta-lactamase (ESBL) producing organism.

101 Typhi isolate showing extended spectrum beta-lactamase (ESBL) production in the Democratic Republic o

102 riaceae suggestive of extended-spectrum beta-lactamase (ESBL) production, carbapenem-resistant Entero

103 ertapenem-susceptible extended-spectrum-beta-lactamase (ESBL)-positive phenotype were assessed for th

104 pics annually acquire extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-PE),

105 vided pivotal data on extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and CRE ca

106 y of studies reported extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and MDR Ac

107 Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae generally

108 haracterized clinical extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and K. pneum

109 two patients in whom extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli bacteremia o

110 reasing prevalence of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli is worrisome

111 depth analysis of 178 extended-spectrum beta-lactamase (ESBL)-producing K. pneumoniae collected from

112 lonephritis caused by extended-spectrum beta-lactamase (ESBL)-producing organisms.

113 infections caused by extended-spectrum beta-lactamase (ESBL)-producing pathogens is recognized globa

114 ne resistance (PMQR), extended-spectrum beta-lactamases (ESBL) and AmpC beta-lactamases.

115 ciated acquisition of extended-spectrum beta-lactamase- (ESBL) and carbapenemase-producing Enterobact

116 lactamases, including extended-spectrum beta-lactamases (ESBLs) and carbapenemases belonging to diffe

117 laboratories test for extended-spectrum beta-lactamases (ESBLs) for epidemiological and infection con

118 and the occurrence of extended-spectrum beta-lactamases (ESBLs) modulated by farming and managerial p

119 ants and producers of extended-spectrum beta-lactamases (ESBLs), AmpCs, K1, and broad-spectrum beta-l

120 ated by the spread of extended-spectrum beta-lactamases (ESBLs), is a very serious medical concern wi

121 onic acid synergy test, and the metallo-beta-lactamase Etest, had specificities of >90% for detecting

122 Using simulations and experiments with beta-lactamase-expressing bacteria, we found that for a given

123 ons are provided for medically relevant beta-lactamase families and various BLI combinations that hav

124 ependent DNA ligase; and Exo, a metallo-beta-lactamase-family nuclease.

125 s conducted on purified PenA1 and AmpC1 beta-lactamases from Burkholderia multivorans ATCC 17616.

126 ine beta-lactamase) but not L1 (metallo beta-lactamase) from the extensively drug resistant human pat

127 a deep mutant library of the bla(ampC) beta-lactamase gene of Escherichia coli, we identified mutati

128 m-negative bacteria (GNB) are numerous; beta-lactamase genes carried on mobile genetic elements are a

129 current genotypic methods (negative for beta-lactamase genes or lacking predictive genotypes).

130 e molecularly characterized to identify beta-lactamase genes.

131 ucing the target drug concentration via beta-lactamases; however, naturally transformable bacteria ha

132 eeded, especially compounds that resist beta-lactamase hydrolysis.

133 Serine active-site beta-lactamases hydrolyze beta-lactam antibiotics through the

134 of inhibitors for NDM-1 and two related beta-lactamases, IMP-1 and VIM-2, was identified.

135 f WhiB4 in coordinating the activity of beta-lactamase in a redox-dependent manner to tolerate AG.

136 ic detection of the OXA-48-type class D beta-lactamases in Enterobacteriaceae is challenging.

137 oduce ESBLs, carbapenemases or multiple beta-lactamases in the same organism.

138 olomycin also strongly inhibits metallo-beta-lactamases in vitro, major contributors to clinical carb

139 ues able to inhibit clinically-relevant beta-lactamases, including AmpC, Extended-Spectrum BLs (ESBL)

140 commonly associated with production of beta-lactamases, including extended-spectrum beta-lactamases

141 y susceptibility to 2 newer beta-lactam/beta-lactamase inhibitor (BL-BLI) combinations, ceftazidime/a

142 NDM is impervious to all existing beta-lactamase inhibitor (BLI) drugs, including the non-beta-

143 s, combinations of a beta-lactam with a beta-lactamase inhibitor (BLI) have been clinically successfu

144 AAI101) is a novel penicillanic sulfone beta-lactamase inhibitor active against a wide range of ESBLs

145 ex with avibactam, a diazabicyclooctane beta-lactamase inhibitor at 1.6-2.0 angstrom resolution.

146 ystallography and the recently approved beta-lactamase inhibitor avibactam to trap the acyl-enzyme co

147 ibitors, such as the derivatives of the beta-lactamase inhibitor avibactam, are closer to the clinic

148 vaborbactam (MEV) is a novel carbapenem-beta-lactamase inhibitor combination antibiotic approved by t

149 illin-tazobactam (P/T) is a beta-lactam-beta-lactamase inhibitor combination frequently used in the h

150 ane/tazobactam is a novel cephalosporin/beta-lactamase inhibitor combination that often retains activ

151 oline, ertapenem, and novel beta-lactam-beta-lactamase inhibitor combinations from January 2017 to De

152 h respect to empirical therapy with new beta-lactamase inhibitor combinations such as ceftazidime/avi

153 by various beta-lactams or beta-lactam-beta-lactamase inhibitor combinations.

154 tions, particularly for new beta-lactam/beta-lactamase inhibitor combinations.

155 e" analogue approach for broad-spectrum beta-lactamase inhibitor development and highlight the abilit

156 Despite major advances in the beta-lactamase inhibitor field, certain enzymes remain refrac

157 Avibactam is a non-beta-lactam beta-lactamase inhibitor for treating complicated urinary tra

158 X-5133 (taniborbactam) is a new type of beta-lactamase inhibitor in clinical development.

159 The beta-lactamase inhibitor relebactam can restore imipenem acti

160 Imipenem combined with the beta-lactamase inhibitor relebactam has broad antibacterial a

161 and mouse models shows that penicillin/beta-lactamase inhibitor susceptibility can be exploited as a

162 bacterial combination consisting of the beta-lactamase inhibitor tazobactam and a fourth-generation c

163 Taniborbactam is the first pan-spectrum beta-lactamase inhibitor to enter clinical development.

164 ebactam (an investigational beta-lactam/beta-lactamase inhibitor).

165 ctericidal activity in combination with beta-lactamase inhibitor, clavulanate (Clav).

166 llin and this activity was inhibited by beta-lactamase inhibitor, i.e. sulbactam.

167 Relebactam, a potent beta-lactamase inhibitor, in combination with Primaxin is an

168 nism to amoxicillin, by repurposing the beta-lactamase inhibitor, relebactam, in combination with the

169 xicillin/clavulanate, a beta-lactam and beta-lactamase inhibitor, respectively.

170 y bioavailable diazabicyclooctane (DBO) beta-lactamase inhibitor.

171 a boronic-acid-containing pan-spectrum beta-lactamase inhibitor.

172 beta-Lactamase inhibitors (BLIs) can be administered in combi

173 Among the antimicrobials, B-lactam with B-lactamase inhibitors (OR 3.65; P < .001), first-generati

174 .15-2.37]) and exposure to beta-lactams/beta-lactamase inhibitors (risk ratio, 1.78 [95% CI, 1.24-2.5

175 icillin MIC >= 256 mug/ml), beta-lactam/beta-lactamase inhibitors and cephalosporins (amoxicillin/cla

176 verview of the most recently identified beta-lactamase inhibitors and of combination therapy is provi

177 Beta-lactamase inhibitors are increasingly used to counteract

178 Second-generation beta-lactamase inhibitors containing a diazabicyclooctane (DB

179 drugs to carbapenems except beta-lactam/beta-lactamase inhibitors for the treatment of bloodstream in

180 Although several new beta-lactamase inhibitors have been approved or are in clinic

181 As a pertinent example, the use of beta lactamase inhibitors in combination with beta-lactam con

182 nicillins when used in combination with beta-lactamase inhibitors such as clavulanic acid.

183 This Perspective is focused on beta-lactamase inhibitors that disable the most prevalent cau

184 cterization of expanded-spectrum serine beta-lactamase inhibitors that potently inhibit clinically re

185 A multiligand set of boronic acid (BA) beta-lactamase inhibitors was obtained using covalent molecul

186 nthesis of new beta-lactam antibiotics, beta-lactamase inhibitors, and bicyclic carbohydrate-beta-lac

187 yclooctanone and cyclic boronate serine beta-lactamase inhibitors, and of progress and strategies tow

188 s provided of the changing landscape of beta-lactamase inhibitors, exemplified by the introduction to

189 vibactam are clinically deployed serine beta-lactamase inhibitors, important as a defence against ant

190 osporins, fluoroquinolones, beta-lactam/beta-lactamase inhibitors, multidrug resistant strains and ca

191 nam-like beta-lactams plus nonclassical beta-lactamase inhibitors, particularly avibactam-like and bi

192 m antibiotics in a manner distinct from beta-lactamase inhibitors.

193 anism distinct from that of traditional beta-lactamase inhibitors.

194 al bacterial resistance mechanisms: (i) beta-lactamase inhibitors; (ii) outer membrane permeabilizers

195 A second focus is beta-lactamase interactions with carbapenems, as carbapenem-r

196 Expression of beta-lactamase is the single most prevalent determinant of an

197 id (BZB), a nanomolar inhibitor of AmpC beta-lactamase (K i = 27 nM), we have identified and characte

198 We expressed a MBLAC2 human beta-lactamase, known as an exosome biogenesis enzyme.

199 we show by NMR spectroscopy, the serine beta-lactamases (KPC-2, SFC-1, CMY-10, OXA-23, and OXA-48) an

200 One of the ARGs, PC1 beta-lactamase may also be a mobile element that facilitates

201 Metallo-beta-lactamases (MbetaLs) are the main mechanism of resistanc

202 jor health threat by expressing metallo-beta-lactamases (MbetaLs), enzymes able to hydrolyse these li

203 g Enterobacteriaceae (CPE) with metallo-beta-lactamases (MbetaLs).

204 emergence and global spread of metallo-beta-lactamase (MBL) mediated resistance, specifically New De

205 Members of the metallo-beta-lactamase (MBL) superfamily of enzymes harbor a highly c

206 antimicrobial susceptibility of metallo-beta-lactamase (MBL)-harboring Enterobacteriaceae We also eva

207 and OXA-type carbapenemases and metallo-beta-lactamases (MBL).

208 Metallo-beta-lactamases (MBLs) degrade a broad spectrum of beta-lacta

209 Two recent examples are metal-dependent beta-lactamases (MBLs) from the marine organisms Novosphingob

210 -lactam antibiotics mediated by metallo-beta-lactamases (MBLs) is a growing problem.

211 rine beta-lactamases (SBLs) and metallo-beta-lactamases (MBLs), especially those with carbapenemase a

212 ) and some clinically important metallo-beta-lactamases (MBLs), including NDM-1 and VIM-1/2.

213 The worldwide dissemination of metallo-beta-lactamases (MBLs), mediating resistance to carbapenem an

214 nd D) and the zinc-dependent or metallo-beta-lactamases (MBLs; class B).

215 ine- and metal-dependent (i.e., metallo-beta-lactamases [MBLs]) carbapenemases when used in conjuncti

216 ombination with amoxicillin to overcome beta-lactamase-mediated antibiotic resistance.

217 Following beta-lactamase-mediated opening of the beta-lactam, the pyrro

218 Understanding the nuances of AmpC beta-lactamase-mediated resistance can be challenging, even f

219 PADs) that can test for the presence of beta-lactamase-mediated resistance.

220 peptide common to all 12 OXA-48 family beta-lactamase members, and YSVVPVYQEFAR, a highly specific p

221 High activity against extended-spectrum beta-lactamase, methicillin-resistant S. aureus, and carbapen

222 dy clone, a protease of interest, and a beta-lactamase modified by insertion of a protease cleavable

223 nalyze an outbreak of New Delhi metallo-beta-lactamase (NDM)-producing K. pneumoniae that occurred in

224 Infections caused by New Delhi metallo-beta-lactamase (NDM)-producing strains of multidrug-resistant

225 CMY-10, OXA-23, and OXA-48) and metallo-beta-lactamases (NDM-1, VIM-1, BcII, CphA, and L1) tested all

226 ses (VIM; n = 27) and New Delhi metallo-beta-lactamases (NDM; n = 13) tested had 100% concordance to

227 iscriminate between clinically-relevant beta-lactamases on the basis of their inhibition profile.

228 Furthermore, in contrast to metallo-beta-lactamases or Klebsiella pneumoniae carbapenemases (KPC)

229 tibiotics are poorly hydrolyzed by most beta-lactamases owing to slow hydrolysis of the acyl-enzyme i

230 at carry carbapenem-hydrolyzing class D beta-lactamases (OXA-23, OXA-24/40 and OXA-48), as well as wi

231 two divergons that control levels of a beta-lactamase, PC1, and a penicillin-binding protein poorly

232 ediate tetracycline resistance) and the beta-lactamase plasmid expressing TEM-135 are associated with

233 am-negative bacteria expressing class A beta-lactamases pose a serious health threat due to their abi

234 All isolates were beta-lactamase positive and were resistant to penicillin, tet

235 valence of intestinal Extended-spectrum Beta-lactamase producing Enterobacteriaceae (ESBL-E) carriage

236 tly, we report the presence of the AmpC beta-lactamase producing gene (CITM) in 4.56% and 3.26% of br

237 nal lineages of ESBL (Extended-Spectrum beta-Lactamase)-producing E. coli belonging to sequence type

238 resistant bacteria is extended-spectrum beta-lactamase-producing bacteria (ESBL-positive = ESBL(+)).

239 biotic resistance to selectively target beta-lactamase-producing bacteria using our prodrug approach,

240 Infections caused by extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) among hosp

241 infection (BSI) with extended spectrum beta-lactamase-producing Enterobacteriaceae (EPE) in previous

242 valence of intestinal extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) carriage

243 red infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) strength

244 re rectal carriers of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E), compare

245 ections (BSIs) due to extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E).

246 Carriers of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) who rec

247 regimens do not cover extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE).

248 digestive tract with extended-spectrum beta-lactamase-producing Enterobacteriaceae during ICU-hospit

249 red colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae in previously non

250 likely to develop an extended-spectrum beta-lactamase-producing Enterobacteriaceae infection (risk r

251 to predict subsequent extended-spectrum beta-lactamase-producing Enterobacteriaceae infection were 95

252 Studies reporting extended-spectrum beta-lactamase-producing Enterobacteriaceae outbreaks or data

253 disk synergy test for extended-spectrum beta-lactamase-producing Enterobacteriaceae phenotypic confir

254 U acquisition rate of extended-spectrum beta-lactamase-producing Enterobacteriaceae ranged from 5% to

255 baumannii (Hungary), extended-spectrum beta-lactamase-producing Escherichia coli (Spain), cefepime-r

256 el of transmission of extended-spectrum beta-lactamase-producing Escherichia coli in both the communi

257 Extended-spectrum beta-lactamase-producing Escherichia coli isolates (ESBL-E co

258 The emergence and global spread of beta-lactamase-producing multi-drug-resistant "superbugs" has

259 an infection with an extended spectrum beta-lactamase-producing organism.

260 erococcus spp. (VRE), extended-spectrum beta-lactamase-producing organisms (ESBL), and carbapenem-res

261 a high prevalence of extended-spectrum beta-lactamase-producing organisms.

262 tams, cephalosporins (extended-spectrum beta-lactamase-producing type SHV-12), and quinolones (plasmi

263 -resistant S. aureus, extended-spectrum beta-lactamase-producing, and carbapenem-resistant Enterobact

264 multidrug resistance, extended spectrum beta-lactamase production and azithromycin resistance.

265 qB are unprecedented within the metallo beta-lactamase protein family and expand the catalytic repert

266 s with genes specifying homologs of a fungal lactamase (renamed prokaryotic 5-oxoprolinase A, pxpA) a

267 of 17 compounds for inhibition of five beta-lactamases representative of enzymes found in pathogenic

268 Despite the long history of beta-lactamase research, we contend that issues including con

269 e in relative abundance of bacteria and beta-lactamase resistance genes (TEM-1) was observed over 6 m

270 zoles, a key subunit present in several beta-lactamase-resistant antibiotics.

271 ws for reassessment of beta-lactams and beta-lactamases role in humans.

272 clooctanes (DBOs) are a class of serine beta-lactamase (SBL) inhibitors that use a strained urea moie

273 am-negative pathogens expressing serine beta-lactamases (SBLs) and metallo-beta-lactamases (MBLs), es

274 e report that VNRX-5133 inhibits serine-beta-lactamases (SBLs) and some clinically important metallo-

275 Class A serine beta-lactamases (SBLs) are key antibiotic resistance determin

276 tion of the class D nucleophilic serine beta-lactamases (SBLs) with carbapenems also produces beta-la

277 ures included evolutionary variation in beta-lactamases, secondary structure identity, tolerance to a

278 roducing (n = 22) and Sao Paulo metallo-beta-lactamase (SPM)-producing (n = 14) isolates.

279 ved in both KPC-2 and non-carbapenemase beta-lactamases, suggesting it promotes carbapenem hydrolysis

280 (IntS11), which belongs to the metallo-beta-lactamase superfamily and is a paralog of CPSF-73, the e

281 ic acid, which suggests that penicillin/beta-lactamase susceptibility is an example of collateral sen

282 en identified as hyperproduction of the beta-lactamase TEM.

283 nicillin disk diffusion test, and three beta-lactamase tests, including the cefoxitin-induced nitroce

284 ase (SYN-004) is an orally administered beta-lactamase that was designed to be given with intravenous

285 one of the residues present in class A beta-lactamases that is under selective pressure due to antib

286 that is hydrolyzed by the enzyme BlaC (beta-lactamase) that is naturally expressed by M. tuberculosi

287 the protease from cleaving the modified beta-lactamase, thereby allowing the cell to survive in the p

288 antibiotics to negate the action of the beta-lactamases, thereby restoring activity of the beta-lacta

289 e also discuss the evolution of metallo-beta-lactamases; this illustrates how rapid antibiotic-mediat

290 biotic for the same binding site on the beta-lactamase, thus generating an evolutionary tradeoff: mut

291 , and evolutionary variation in class A beta-lactamases to be the somewhat predictive of InDel fitnes

292 l over activity of any pockets found in beta-lactamases to date.

293 d evolution of four orthologous metallo-beta-lactamases toward a new function and found that differen

294 A total of 88 New Delhi metallo-beta-lactamases-type carbapenem-resistant Escherichia coli (N

295 We assayed a TEM-1 beta-lactamase variant and levoglucosan kinase (LGK) using ye

296 entified in several inhibitor-resistant beta-lactamase variants is associated with decreased potency

297 ng, all Verona integrin-encoded metallo-beta-lactamases (VIM; n = 27) and New Delhi metallo-beta-lact

298 Here we show that for CTX-M-14 beta-lactamase, whereas Lys(234) is required for hydrolysis o

299 n the 5' end of the RNA under study and beta-lactamase, which is able to produce a colorimetric respo

300 nt of the nucleophilic serine of serine beta-lactamases with cysteine yields enzymes which fragment b